Prestige Consumer Healthcare In
60.71-1.32 (-2.13%)
Oct 29, 4:00:02 PM EDT · NYSE · PBH · USD
Key Stats
Market Cap
2.99BP/E (TTM)
14.25Basic EPS (TTM)
4.26Dividend Yield
0%Recent Filings
8-K
Acquires Pillar5 to boost eye care supply
Prestige Consumer Healthcare agreed to buy Pillar5 Pharma, its Clear Eyes supplier, for CAD 150 million in cash on August 4, 2025, aiming to fix supply shortages that hammered Q1 revenue down 6.6% to $249.5 million. The deal, set to close in Q3 fiscal 2026, should secure long-term eye care capacity while staying neutral to EPS. Supply woes persist into H1, but 2H improvements loom. Risks hinge on meeting closing conditions. 
10-Q
Q1 FY2026 results
Prestige Consumer Healthcare's Q1 FY2026 revenues fell 6.6% y/y to $249.5M, driven by supply shortages in Eye & Ear Care that slashed sales 35.9% y/y, yet gross margins expanded to 56.2% from 54.7% on better product mix and lower air freight. Operating income held steady at $71.8M, while net income dipped 3.2% y/y to $47.5M with diluted EPS of $0.95 on 49.8M shares—consistent with no material anti-dilution. Cash swelled to $139.5M after $79.0M operating cash flow and $1.9M capex for $77.1M free cash flow (derived), funding $34.8M share repurchases amid $1.0B fixed-rate debt and $173.2M revolver availability. The pending $100M acquisition of Pillar5 Pharma eyes bolstering eye care capacity, closing Q3 FY2026. Supply chain disruptions linger as a key risk. 
10-K
FY2025 results
Prestige Consumer Healthcare delivered steady FY2025 results, with total revenues edging up 1.1% year-over-year to $1.14 billion, driven by a 6.4% surge in the International OTC Healthcare segment that offset flat North American performance; gastrointestinal products fueled the international momentum, while cough & cold sales dipped 11.8% domestically amid supply constraints. Q4 wrapped the year on a resilient note, with gross margins expanding to 55.8% from 55.5% thanks to lower freight costs and favorable product mix, though non-strategic brand impairments of $12.5 million tempered operating income to $336.8 million. Contribution margins held firm at 42.1%, bolstered by disciplined marketing spend. The company strengthened its liquidity posture, repaying the full $135 million term loan and advancing $51.5 million in share buybacks under its $300 million program, leaving $248 million available. No formal FY2026 guidance was issued, but management eyes continued international growth. Supply chain disruptions, especially in eye care, remain a key risk that could stall quarterly momentum. 
8-K
Record FY25 revenue, EPS growth
Prestige Consumer Healthcare reported fiscal 2025 revenue of $1,137.8 million, up 1.1% from prior year, with organic growth of 1.2% fueled by strong international sales and GI category gains, though offset by cough & cold declines. Adjusted diluted EPS rose 7.4% to $4.52, backed by $243.3 million in free cash flow that cut leverage to 2.4x and funded $51.5 million in share repurchases. Solid execution shines. Fiscal 2026 outlook projects 1-2% organic revenue growth and EPS of $4.70-$4.82, despite a $15 million tariff headwind. 
8-K
Record Q3 revenue, EPS up 15%
Prestige Consumer Healthcare reported third-quarter fiscal 2025 revenues of $290.3 million, up 2.7% from last year, fueled by 11.3% international growth and sequential Clear Eyes improvement, though offset by cough and cold declines. Diluted EPS rose 15% to $1.22, with leverage dropping to 2.5x after paying off variable debt and repurchasing $40.2 million in shares. The company raised its full-year adjusted EPS outlook to $4.50, signaling stronger profitability ahead. Cash flow remains robust. 
IPO
Employees
Sector
Industry
BHC
Bausch Health Companies Inc.
5.90-0.29
COTY
Coty Inc.
3.95-0.07
HIMS
Hims & Hers Health, Inc.
46.63-0.49
HLN
Haleon plc
9.05-0.07
KVUE
Kenvue Inc.
14.31-0.20
PAHC
Phibro Animal Health Corporatio
41.19-0.49
PFE
Pfizer, Inc.
24.29-0.21
PRGO
Perrigo Company plc
21.28-0.32
SNYR
Synergy CHC Corp.
2.26-0.14
VTRS
Viatris Inc.
10.27-0.02